cardiovascular Tag

15 Jul

Posted at 11:53h in Dental Research, Heart Disease

For decades, medical science treated the human body as a collection of isolated systems, often viewing oral care as a separate discipline entirely. However, modern research is rapidly proving that overall health is deeply interconnected. Nowhere is this more apparent than in the relationship between the mouth and the rest of the body. Preventable oral health conditions, including severe gum disease and untreated decay, currently contribute to approximately 4.5 percent of all non-fatal disease burden in Australia. This growing body of evidence highlights that a healthy mouth is not just about a bright smile, but a fundamental requirement for long-term systemic wellbeing.

For patients in Victoria, working with experienced Dentists in East Melbourne provides access to comprehensive periodontal assessments that address these systemic risks before they progress.

[caption id="attachment_75001" align="aligncenter" width="500"]periodontal-disease-heart-disease-pexels Photo by Bijen Amatya[/caption]

14 Jul

Posted at 19:54h in Dental Research, Heart Disease

MedicalResearch.com Interview with:

Chenyang Li, M.D.

Department of Cardiology

Fuwai Hospital, National Center for Cardiovascular Diseases

Chinese Academy of Medical Sciences & Peking Union Medical College

[caption id="attachment_74997" align="alignleft" width="200"]Dr. Chenyang Li Dr. Chenyang Li[/caption]

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Li: Calcific aortic valve stenosis (CAVS) is one of the most common valvular heart diseases in older adults, affecting approximately 2–7% of individuals over the age of 65. Although chronic inflammation is increasingly recognized as an important contributor to disease progression, the upstream triggers remain incompletely understood.

04 Feb

Posted at 11:14h in Author Interviews, Brigham & Women's - Harvard, Heart Disease, Nature
MedicalResearch.com Interview with: [caption id="attachment_56558" align="alignleft" width="200"]HUGO AERTS, PhD Dana-Farber Cancer Institute Associate Professor, Brigham and Women's Hospital Harvard Medical School Director, Program for Artificial Intelligence in Medicine Brigham And Women's Hospital Dr. Aerts[/caption] Dr. Hugo Aerts, PhD Dana-Farber Cancer Institute Associate Professor, Brigham and Women's Hospital Harvard Medical School Director, Program for Artificial Intelligence in Medicine Brigham And Women's Hospital  MedicalResearch.com: Deep convolutional neural networks to predict cardiovascular risk from computed tomography  Response: Cardiovascular disease is the most common preventable cause of death in Europe and the United States. Effective lifestyle and pharmacological prevention is available, but identifying those who would benefit most remains an ongoing challenge. Hence, efforts are needed to further improve cardiovascular risk prediction and stratification on an individual basis. One of the strongest known predictors for adverse cardiovascular events is coronary artery calcification, which can be quantified on computed tomography (CT). The CT coronary calcium score is a measure of the burden of coronary atherosclerosis and is one of the most widely accepted measures of cardiovascular risk. Recent strides in artificial intelligence, deep learning in particular, have shown its viability in several medical applications such as medical diagnostic and imaging, risk management, or virtual assistants. A major advantage is that deep learning can automate complex assessments that previously could only be done by radiologists, but now is feasible at scale with a higher speed and lower cost. This makes deep learning a promising technology for automating cardiovascular event prediction from imaging. However, before clinical introduction can be considered, generalizability of these systems needs to be demonstrated as they need to be able to predict cardiovascular events of asymptomatic and symptomatic individuals across multiple clinical scenarios, and work robustly on data from multiple institutions.

10 Sep

Posted at 10:55h in Author Interviews, Heart Disease, JAMA
MedicalResearch.com Interview with: [caption id="attachment_51215" align="alignleft" width="200"]Nariman Sepehrvand, MD Research Associate & PhD Candidate Canadian VIGOUR Centre, and Department of Medicine, University of Alberta, Edmonton, Canada Dr. Sepehrvand[/caption] Nariman Sepehrvand, MD Research Associate & PhD Candidate Canadian VIGOUR Centre, and Department of Medicine, University of Alberta, Edmonton, Canada Medical Research: Can you tell us a little bit about the background of this study? Dr. Sepehrvand: As you know the traditional randomized clinical trials (RCT) have been criticized from time to time for the lack of generalizability, high costs and lengthy processes. Pragmatic trials with the primary goal of informing patients, clinicians, healthcare administrators and policy-makers about the effectiveness of biomedical and behavioral interventions have the potential to address those shortcomings by enrolling a population representative of the populations in which the intervention will be eventually applied to and by streamlining and simplifying the trial-related procedures. We knew about the challenges that trialists encounter in the design and implementation of pragmatic trials, so we were wondering how pragmatic or explanatory are cardiovascular (CV) RCTs and if there has been any change over time!

17 Apr

Posted at 18:38h in Author Interviews, Heart Disease, JAMA, Lipids
MedicalResearch.com Interview with: [caption id="attachment_41237" align="alignleft" width="142"]Dr. Jennifer Robinson, MD MPH professor of epidemiology, University of Iowa College of Public Health. CREDIT Tom Langdon Dr. Robinson[/caption] Dr. Jennifer Robinson, MD MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center Department of Epidemiology University of Iowa MedicalResearch.com: What is the background for this study? Response: Compared to previous placebo-controlled statin trials, the FOURIER trial where all patients were on high or moderate intensity statin, had no reduction in cardiovascular or total mortality and the reduction in cardiovascular events was less than expected.  However, other PCSK9 inhibitor trials performed in populations with higher baseline low density lipoprotein cholesterol (LDL-C) had cardiovascular risk reductions similar to that in the statin trails.